FloraWorks, a leading cannabinoid therapeutics company, conducted a groundbreaking double-blind, randomized, placebo-controlled trial on its flagship product, TruCBN™—"an ultra-pure cannabinol" and now, "the first CBN ingredient with clinically validated claims for treating sleep disturbances."
The clinical trial was independently conducted by Radicle Science. The study involved over 1,000 participants in the U.S. who received different doses of TruCBN™, melatonin, or a placebo. One of the main findings from the trial pointed out that the group taking 50 mg of FloraWorks' CBN ingredient "showed a significant improvement in sleep compared to placebo." Additionally, the TruCBN™ group had "slightly better sleep improvements compared to [the individuals taking] 4 mg of melatonin."
FloraWorks' CEO and co-founder, Alleh Lindquist, emphasized that these findings open the door to more effective sleep solutions that will benefit millions.
Sleep-Supporting CBN Ingredients
Floraworks' Ultra-Pure Cannabinol is Clinically Proven
Trend Themes
1. Clinically Validated CBN Ingredients - FloraWorks' groundbreaking clinical trial validates the effectiveness of their ultra-pure cannabinol ingredient in treating sleep disturbances.
2. Improving Sleep Solutions - The study highlights the potential for more effective sleep solutions that can benefit millions of people.
3. CBN Vs Melatonin for Sleep - Comparison between FloraWorks' CBN ingredient and melatonin reveals slightly better sleep improvements with CBN.
Industry Implications
1. Cannabinoid Therapeutics - The clinically validated CBN ingredient presents an opportunity for companies in the cannabinoid therapeutics industry to develop more effective sleep products.
2. Sleep Solutions - The study results open up opportunities for the sleep solutions industry to explore innovative products that can provide better sleep outcomes.
3. Clinical Research and Trials - The groundbreaking clinical trial conducted by FloraWorks and Radicle Science highlights the importance of clinical research in validating and improving sleep-related therapies.